Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 1;23(1):493. doi: 10.3390/ijms23010493

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Inhibition of Syk causes the same extent of disaggregation observed with antagonists of adenosine diphosphate (ADP) and thromboxane A₂ (TxA₂). Recalcified blood was perfused for 7 min on Horm collagen at 37 °C at arterial shear (1000 s⁻¹), and post-perfused for 10 min with rinse buffer with vehicle (DMSO) or inhibitor of Syk, Src or Btk (PRT-060318 10 µM, dasatinib 10 µM or ibrutinib 7 µM, respectively). (A) Representative images of aggregates at 0, 5, and 10 min of post-perfusion with vehicle, PRT-060318 (n = 5) or dasatinib (n = 6). (B–D) Graphs showing extent of disaggregation, as measured from scores of thrombus morphology, contraction and multilayer,¹⁶ at every 60 s (Bi,Ci,D) or at 10 min (Bii,Cii) of post-perfusion with either vehicle, PRT-060318 (PRT) (Bi,ii), dasatinib (Ci,ii) or ibrutinib (D), alone or combined with indomethacin (Indo, 10 µM) and ticagrelor (Tica, 10 µM). Scale bar = 50 µm. Data are shown as mean ± s.e.m. * p < 0.05, ** p < 0.005, *** p < 0.0005, one-tailed paired Student’s t-test.

Inhibition of Syk causes the same extent of disaggregation observed with antagonists of adenosine diphosphate (ADP) and thromboxane A₂ (TxA₂). Recalcified blood was perfused for 7 min on Horm collagen at 37 °C at arterial shear (1000 s⁻¹), and post-perfused for 10 min with rinse buffer with vehicle (DMSO) or inhibitor of Syk, Src or Btk (PRT-060318 10 µM, dasatinib 10 µM or ibrutinib 7 µM, respectively). (A) Representative images of aggregates at 0, 5, and 10 min of post-perfusion with vehicle, PRT-060318 (n = 5) or dasatinib (n = 6). (B–D) Graphs showing extent of disaggregation, as measured from scores of thrombus morphology, contraction and multilayer,¹⁶ at every 60 s (Bi,Ci,D) or at 10 min (Bii,Cii) of post-perfusion with either vehicle, PRT-060318 (PRT) (Bi,ii), dasatinib (Ci,ii) or ibrutinib (D), alone or combined with indomethacin (Indo, 10 µM) and ticagrelor (Tica, 10 µM). Scale bar = 50 µm. Data are shown as mean ± s.e.m. * p < 0.05, ** p < 0.005, *** p < 0.0005, one-tailed paired Student’s t-test.